Questions to Ask About Leukemia Treatment

"Leukemia" is not a diagnosis on its own. The four main adult forms differ in speed and in treatment. They also differ in how many people they affect. Here are the American Cancer Society's projections for the United States in 2026, the numbers SEER Stat Facts publishes and labels as ACS work.

• Chronic lymphocytic leukemia (CLL): 22,760 new cases, 4,350 deaths.
• Acute myeloid leukemia (AML): 22,720 new cases, 11,500 deaths.
• Chronic myeloid leukemia (CML): 9,650 new cases, 1,170 deaths.
• Acute lymphoblastic leukemia (ALL): 6,250 new cases, 1,600 deaths.

Compare the first two rows. CLL has about as many projected new cases as AML but roughly a quarter of the projected deaths. Read that as a rough signal that these are different illnesses, not as a prognosis: counts of new cases and deaths in the same calendar year describe two different populations and cannot be divided to give anyone's odds. "Acute" and "chronic" actually describe the cells — acute leukemias are built from immature blasts and move fast, chronic ones from more mature cells and usually move slowly. Nothing on this page substitutes for the exact WHO or ICC diagnosis, which has to be in hand before any treatment decision is made.

For AML, NCI notes that symptoms often build over a 4- to 6-week period before diagnosis. The first symptoms are weakness, fever, infection, pallor, and bleeding. Those come from leukemia cells crowding the marrow. That crowding produces granulocytopenia, anemia, and thrombocytopenia at once.

AML is uncommon before age 45. The median age at diagnosis is 69. In the SEER data NCI quotes, covering 2014 to 2020, 31.9% of people with AML were alive 5 years after diagnosis. SEER's own stat facts page now covers people diagnosed between 2016 and 2022 and puts it at 33.4%.

The treatment goal is stated without hedging. Therapy should be aggressive enough to reach complete remission. Partial remission offers no substantial survival benefit. Roughly 60% to 70% of adults with AML can be expected to reach complete remission after proper induction therapy. More than 25% of all adults with AML can be expected to survive 3 or more years, and may be cured. That is about 45% of those who reach complete remission.

That framing matters for decisions. In AML, "some response" is not a goal. In some other cancers it can be.

Two kinds of testing carry the most weight, and NCI says so directly. Cytogenetic and molecular analyses provide the strongest prognostic information available. They predict the outcome of both remission induction and consolidation therapy.

About half of people with AML carry chromosomal abnormalities. For that reason, conventional cytogenetic analysis remains mandatory when AML is suspected. Molecular testing then looks for recurrent somatic variants. NCI names the routine ones. They are NPM1, FLT3, CEBPA, and RUNX1, among others. Cytogenetic and molecular results are then combined into distinct prognostic groups.

Beyond genetics, NCI lists additional adverse prognostic factors:

• Age at diagnosis. Remission rates in adult AML fall as age rises. The expected rate is above 65% for people younger than 60. Once reached, remission may be shorter in older patients. Illness and death during induction also appear to track directly with age.
• Central nervous system involvement with leukemia.
• Systemic infection at diagnosis.
• A white blood cell count above 100,000/mm³ at diagnosis.
• Therapy-related myeloid neoplasms, arising from previous alkylating agents and radiation therapy.
• A history of myelodysplastic syndrome or another preceding blood disorder.

ALL arises when B-cell or T-cell progenitor cells turn malignant. It is more common in children, but occurs at any age. Lymphoblasts build up in the marrow, or at sites outside it. That usually suppresses normal blood production.

Lineage is identified by surface markers, and the two panels differ:

• Precursor B-cell ALL cells typically carry CD10, CD19, and CD34 on the surface, plus nuclear terminal deoxynucleotide transferase, abbreviated TdT.
• Precursor T-cell ALL cells commonly carry CD2, CD3, CD7, CD34, and TdT.

Then there is the Philadelphia chromosome. Its frequency differs sharply between the two acute leukemias. It occurs in only 1% to 2% of people with AML. It occurs in about 20% of adults with ALL, and in a small percentage of children.

One nuance is easy to miss. Take most children, and more than half of adults, with Philadelphia-positive ALL. Their underlying molecular abnormality differs from the one in Philadelphia-positive CML. Same chromosome finding, different molecular event.

CLL is a disorder of lymphocytes. They look mature under the microscope, but are less mature in immune terms. They build up steadily in the blood, the bone marrow, and lymphatic tissue.

The course runs from an indolent lymphocytosis to something much broader. Indolent lymphocytosis means a raised lymphocyte count with nothing else evident. The later state is general swelling of lymphatic tissue with pancytopenia. Pancytopenia means low counts across all cell lines. Its complications are hemorrhage and infection, and those are a major cause of death.

Immune problems complicate management on their own. The three named are Coombs-positive hemolytic anemia, immune thrombocytopenia, and low immunoglobulin levels.

The examination is more hands-on than most people expect. NCI includes measuring the largest palpable lymph nodes in two directions. Those are checked at the neck, armpit, and groin. The liver and spleen are also measured below the rib margins, by hand. Blood work includes a complete blood count with differential. It also includes a chemistry panel covering creatinine, bilirubin, transaminases, and alkaline phosphatase.

Several prognostic details are worth asking about by name:

• Anemia and low platelets are adverse signs, but only when extensive marrow involvement by CLL causes them. Autoimmune hemolytic anemia and immune thrombocytopenic purpura do not confer a worse prognosis.
• Lymphocyte doubling time. A white blood cell count that doubles in less than 1 year implies a worse prognosis.
• Beta-2-microglobulin. Higher levels imply a worse prognosis.

There is also a specific rule about scans. PET-CT should only be used in four settings. Recurrent fever. Soaking night sweats. Weight loss of more than 10% of baseline weight over 6 months. Or rapidly growing lymph nodes. Those findings may signal Richter transformation, meaning CLL turning into a diffuse large B-cell lymphoma. One retrospective review covered 432 patients. Of those, 209 had a maximum standardized uptake value of 5 or higher. Among them, 80% had histologically aggressive CLL or Richter syndrome. When that value reached 10 or higher, 5-year overall survival was only 30%.

Richter transformation happens in 2% to 10% of patients with CLL. The outlook is poor when it follows earlier CLL therapy. That earlier therapy may be chemoimmunotherapy, a Bruton tyrosine kinase inhibitor, or venetoclax. In those cases median survival runs 6 to 14 months.

CML is defined by the BCR::ABL1 fusion gene. It is present in more than 95% of cases, as the Philadelphia chromosome. Oral tyrosine kinase inhibitors block the abnormal protein it produces. With those drugs, NCI projects median survival approaching normal life expectancy for most patients. Our page on CML symptoms covers how it presents, and how phase is tracked.

• Which leukemia is this, by full name, and is it acute or chronic?
• For AML or ALL: has conventional cytogenetic analysis been done, and what did it show?
• For AML: what did testing for NPM1, FLT3, CEBPA, and RUNX1 show, and which prognostic group results?
• For AML: what was the white blood cell count at diagnosis, and is there CNS involvement or active infection?
• For ALL: is this B-lineage or T-lineage, and is it Philadelphia-positive?
• For CLL: is any anemia or low platelet count from marrow involvement, or from an autoimmune cause?
• For CLL: what is the lymphocyte doubling time, and what is the beta-2-microglobulin level?
• Is the goal complete remission, and what happens if only a partial response is achieved?
• Is there a prior blood disorder or previous chemotherapy or radiation in the history?

See leukemia for the overview and acute versus chronic leukemia for the distinction that drives everything here. This page is a question list drawn from NCI. It does not recommend a treatment.

• NCI PDQ — Acute Myeloid Leukemia Treatment, health professional version
• NCI PDQ — Adult Acute Lymphoblastic Leukemia Treatment, health professional version
• NCI PDQ — Chronic Lymphocytic Leukemia Treatment, health professional version
• NCI PDQ — Chronic Myeloid Leukemia Treatment, health professional version
• American Cancer Society — Cancer Facts & Figures